In: In vivo CAR-T
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo CD19 CAR-T, mRNA in CD8-targeted lipid nanoparticles
- How it’s given
- “Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.”In the company’s words, NCT07556120 on ClinicalTrials.gov
- Tested for
- Generalized Myasthenia Gravis, Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
- Main trialPhase 1
- “This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.”In the company’s words, NCT07556120 on ClinicalTrials.gov
Coming up2
- 31 May 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 31 May 2027 | Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG) | |
| Phase 1Recruiting | 31 Dec 2027 | Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026